Sirna Therapeutics, Inc.

Ribozyme Pharmaceuticals, Incorporated

Other

Chiron Corporation

Biovector Therapeutics, S.a.

Novartis Vaccines & Diagnostics, Gmbh

Pamela Pavco

James A McSwiggen

Dan T Stinchcomb

Jaime A Escobedo

Leonid Beigelman

Kenneth G Draper

Chandra Vargeese

Nassim Usman

Weimin Wang

Thale Jarvis

James D Thompson

James Mcswiggen

John Gustofson

Daniel Stinchcomb

Shawn Patrick Zinnen

Peter Haeberli

Tongqian Chen

David Morrissey

Kathy L Fosnaugh

Bharat Chowrira

Ignacio De Miguel

Didier Betbeder

Roger Kravtzoff

Dennis G Macejak

Narendra K Vaish

Sophie Sixou

Sharon F Jamison

Dennis Macejak

Victor Mokler

Dan T Stinchomb

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity.

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.

Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)

The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

The invention relates to an ionic conjugate, which is stable in a biological medium, and which is comprised of a particle vector with at least one cationic, nonliquid, hydrophilic nucleus and of polyanionic oligonucleotides. The invention further concerns the pharmaceutical compositions containing these conjugates and the use of a particle vector to carry the oligonucleotides to the cells.

Conjugates of a particle vector and oligonucleotides, process for their preparation, and pharmaceutical compositions containing them

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of an arthritic condition.

Method of reducing stromelysin RNA via ribozymes

Stromelysin targeted ribozymes

Growing community of inventors

Lafayette, CO, United States of America

Pamela Pavco